Navigation Links
Haemonetics Completes Hemerus Medical, LLC Acquisition

BRAINTREE, Mass., May 1, 2013 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that it has completed its previously announced acquisition of the assets of Hemerus Medical, LLC ("Hemerus"), a Minnesota-based company that develops innovative technologies for the collection of whole blood and for the processing and storage of blood components. 

(Logo: )

Haemonetics recently learned that the U.S. FDA approved Hemerus' New Drug Application for the SOLX® whole blood collection system for eight hour storage of whole blood.  Hemerus previously received CE Marking (Conformite Europeenne) in the European Union to market SOLX as the world's first 56-day red blood cell storage solution.  Haemonetics paid $23 million cash at the April 30 closing and, including $1 million paid early in fiscal 2013, has paid $24 million to date.  Haemonetics will pay an additional $3 million upon a further FDA approval of the SOLX solution for 24 hour storage of whole blood prior to processing, and will pay up to $14 million on future sales of SOLX-based products. 

As Haemonetics' delivers its automated whole blood collection system, it expects SOLX to contribute to market adoption of the whole blood product suite as it brings benefits to blood center customers that are not available today. 

Brian Concannon , President and CEO, commented: "The addition of Hemerus' SOLX collection system complements the portfolio of whole blood collection, filtration and processing product lines we recently acquired.  We look forward to bringing this new science for red cell storage to our blood center customers as they seek ways to lower the costs of collecting blood and blood components."

Haemonetics is a global healthcare company dedicated to providing innovative blood management solutions for our customers.  Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world.  Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services.  To learn more about Haemonetics, visit our web site at             

This release contains forward-looking statements that are not historical facts. Haemonetics has identified some of these forward-looking statements with words like "will," "expect," "intend," "believe," "may," "could," "would," "might," "possible," "plan," "anticipate," or "continue," the negative of these words, other terms of similar meaning or the use of future dates.  Forward-looking statements in this release include without limitation statements regarding (i) the future FDA approvals, (ii) the effect of the transaction on Haemonetics' business and competitive position, (iii) future innovation and (iv) Haemonetics' future financial performance and financial condition. Information set forth in this press release is current as of today and the Company undertakes no duty or obligation to update this information.

Investors and security holders are cautioned not to place undue reliance on these forward-looking statements.  These forward-looking statements are based on estimates and assumptions made by Haemonetics' management and are believed to be reasonable, though inherently uncertain and difficult to predict. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, including: (i) a governmental entity's prohibition, delay or refusal to grant approval for the products discussed; (ii) our ability to successfully design, manufacture and sell an automated whole blood collection system; (iii) our ability to manufacture and sell SOLX to blood center customers, (iii) the effects of disruption from the transaction making it more difficult to maintain relationships with employees, customers, vendors and other business partners; (iv) the risk that stockholder litigation in connection with the transaction may result in significant costs of defense, indemnification and liability; other business effects, including the effects of industry, economic or political conditions outside of Haemonetics' control; (v) transaction costs; actual or contingent liabilities; and (vi) other risks and uncertainties discussed in Haemonetics' filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections of Haemonetics' most recent annual report on Form 10-K and quarterly reports on Form 10-Q.

Gerry Gould , VP-Investor Relations
Tel. (781) 356-9402
Alt. (781) 356-9613

SOURCE Haemonetics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Haemonetics Reports 4th Quarter Fiscal 2013 Revenue Up 34% and Adjusted EPS of $0.48; Fourth Quarter and Full Year Organic Revenue Up 4% and Full Year Adjusted EPS of $1.71; Completes Hemerus Medical, LLC Acquisition and Provides Fiscal 2014 Guidanc
2. Haemonetics Sets Date for Investor/Analyst Meeting
3. Haemonetics Reports 3rd Quarter Fiscal 2013 Revenue Up 29% and $0.50 Adjusted EPS; Year-To-Date Organic Revenue Up 3%; Reaffirms Fiscal 2013 Adjusted EPS Guidance of $1.65-$1.70
4. Haemonetics Provides Update on Hemerus Medical, LLC Acquisition
5. Haemonetics Completes Acquisition of Palls Transfusion Medicine Business
6. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
7. Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC
8. Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
9. Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.
10. Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee
11. PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie voor ... ) --> ... ) Uit ... Centrum (LUMC) blijkt ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The print component ... Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of ... distributed nationally, through a vast social media strategy and across a network of ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group ... group of Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec ...
(Date:11/27/2015)... ... ... CBD College is proud to announce that on November 20th, ... its Diagnostic Medical Sonography program. CBD College is honored to join this very short ... universities in the state of California make the cut. CBD College is officially the ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., ... the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 ... brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... Representative. As a franchise owner, Somu now offers travelers, value and care based ... packages, private cruise sales, as well as, cabin upgrades and special amenities such ...
Breaking Medicine News(10 mins):